Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
European Center for Disease Prevention and Control U.S. Centers for Disease Control and Prevention, Infectious Disease Society of America (IDSA) Vaccine Research Center Information concerning vaccine research clinical trials for Emerging and re-Emerging Infectious Diseases. Microbes & Infection (journal)
Christopher Hitchens (13 April 1949 – 15 December 2011) was a British and American author, polemicist, debater and journalist who in his youth took part in demonstrations against the Vietnam War, joined organisations such as the International Socialists while at university and began to identify as a socialist. However, after 9/11 he no longer regarded himself as a socialist and his political thinking became largely dominated by the issue of defending civilization from terrorists and against the totalitarian regimes that protect them. Hitchens nonetheless continued to identify as a Marxist, endorsing the materialist conception of history, but believed that Karl Marx had underestimated the revolutionary nature of capitalism. He sympathized with libertarian ideals of limited state interference, but considered libertarianism not to be a viable system. In the 2000 U.S. presidential election, he supported the Green Party candidate Ralph Nader. After 9/11, Hitchens advocated for the invasion of Iraq. In the 2004 election, he very slightly favored the incumbent Republican President George W. Bush or was neutral and in 2008 he favored the Democratic candidate Barack Obama over John McCain despite being critical of both of them.
== Prevention == Complications of postsurgical wounds can be reduced before, during and after surgery. Some measures such as antibiotic prophylaxis before caesarean section and hernial repair are useful in reducing surgical site infection. Intravenous prophylactic antibiotics are recommended, to be administered within one hour from the beginning of the surgical procedure. In addition to i.v. prophylaxis, oral antibiotic prophylaxis has been demonstrated to be beneficial in reducing surgical site infections after elective large bowel surgery. Adding a mechanical bowel cleansing in these patients might not be beneficial after colonic resection, but is still used and recommended by many before rectal resection (ideally in combination with oral antibiotics) However, some options include antibiotic coated sutures, antibiotic impregnated cement or locally administered paste or gel. Of note, a recent randomised controlled trial performed in low- and middle-income countries did not report any reduction in surgical site infection after abdominal surgery with antiseptic (triclosan-coated) sutures. There is also evidence that adhesive tapes increase infection risks. Before surgery, clinicians can treat the patient to reduce hemoglobin A1c levels to less than 7%. Those anticipating surgery can reduce their risk of complications by stopping smoking thirty days prior to surgery. The patient's skin can be evaluated for the presence of Staphylococcus aureus prior to surgery since this bacterium causes wound infections in postoperative wounds.
Sources: en.wikipedia.org
=== Infection === Common infectious causes of back pain include osteomyelitis, septic discitis, paraspinal abscess and epidural abscess. Infectious causes that lead to back pain involve various structures surrounding the spine. Osteomyelitis is the bacterial infection of the bone. Vertebral osteomyelitis is most commonly caused by staphylococci. Risk factors include skin infection, urinary tract infection, IV catheter use, IV drug use, previous endocarditis and lung disease. Spinal epidural abscess is commonly caused by severe infection with bacteremia. Risk factors include recent administration of epidurals, IV drug use or recent infection.
== Z == Zaitsev's rule Zeisel determination Zerevitinov determination, Zerewitinoff determination Ziegler condensation Ziegler method Zimmermann reaction Zincke disulfide cleavage Zincke nitration Zincke reaction Zincke–Suhl reaction Zinin reduction
The equation displayed on the chart gives a means for calculating the absorbance and therefore concentration of the unknown samples. In Graph 1, x is concentration and y is absorbance, so one must rearrange the equation to solve for x and enter the absorbance of the measured unknown. It is likely that the unknown will have absorbance numbers outside the range of the standard. These should not be included calculations, as the equation given cannot apply to numbers outside of its limitations. In a large scale, one must compute the extinction coefficient using the Beer-Lambert Law A=εLC in which A is the measured absorbance, ε is the slope of the standard curve, L is the length of the cuvette, and C is the concentration being determined. In a micro scale, a cuvette may not be used and therefore one only has to rearrange to solve for x.
Sources: en.wikipedia.org
2002: Anthony Ler Wee Teang was hanged on 13 December 2002 for hiring a teenager to murder his wife. 2003: Kanesan Ratnam, a prisoner who killed his cellmate Shankar Suppiahmaniam by strangulation at Queenstown Remand Prison. Kanesan, who was in remand for a charge of rape, was sentenced to death and later hanged on 10 January 2003. 2004: Soosainathan Dass Saminathan, a jobless Singaporean found guilty of murdering a six-month-old Indonesian baby girl after he raped her. He was hanged on 21 May 2004. 2006: Took Leng How, a Malaysian hanged on 3 November 2006 for the 2004 murder of an eight-year-old girl. 2008: Mohammed Ali bin Johari was hanged on 19 December 2008 for the 2006 rape and murder of his stepdaughter. 2011: Nakamuthu Balakrishnan, a Singaporean sentenced to death for murdering a lorry driver during a S$1.3 million mobile phone heist. His date of death was 8 July 2011. 2014: Wang Zhijian, a Chinese national sentenced to death in 2012 for the 2008 Yishun triple murders. The Court of Appeal dismissed his appeal in 2014 and he was hanged on 20 May 2016 along with Kho Jabing. 2015: Muhammad Kadar, an odd-job labourer charged with knifing a 69-year-old housewife 110 times and therefore killed her during a robbery in 2005. He was hanged ten years later on 17 April 2015. 2016: Kho Jabing, a Malaysian hanged on 20 May 2016 for the 2008 robbery and murder of a construction worker. Wang Zhijian the perpetrator of the 2008 Yishun Triple Murders was also executed together with him.
Australasian Association of Clinical Geneticists Australasian Society of Diagnostic Genomics Australasian Society of Genetic Counsellors Australasian Society for Inborn Errors of Metabolism Australasian Cancer Genetics Group
=== Stress and anxiety === In vitro studies examining the effects of CRH1 antagonists on the hypothalamic–pituitary–adrenal axis showed that antalarmin inhibited ACTH release in rat anterior pituitary cells, as well as inhibited cortisol synthesis and release in human adrenal cells. In vivo studies revealed that pre-treating rats with antalarmin inhibited increases in plasma ACTH following CRH injection (i.v.), with no effect on baseline levels. However, another study demonstrated that 8 weeks of antalarmin administered twice daily (i.p.) in rats significantly lowered basal ACTH and corticosterone levels, resulting in reduced adrenocortical responsiveness to ACTH. When antalarmin was administered to primates, it also inhibited increases in plasma ACTH, as well as prevented the anxiety response produced by a social stressor (e.g. presentation of another male in an unfamiliar environment). With regards to neurochemical effects, antalarmin has been shown to inhibit increases in extracellular cortical norepinephrine induced by rat tail pinch, suggesting that CHR1 receptors may be implicated in stress-evoked norepinephrine release in the cortex. Antalarmin was also shown to have electrophysiological effects by partially reversing the inhibition of neuronal firing in the dorsal raphe nucleus that occurs following intracerebroventricular (i.c.v) administration of CRH. Studies using CRH receptor antagonists such as antalarmin in anxiety models have shown that these agents produce effects similar to clinically effective anxiolytics.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.